Drugs / Tumor lysate, particle only (TLPO) vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06175221 | Nov 2023 → Jul 2025 | cancer, metastatic neoplasm | Elios Therapeutics, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor lysate, particle only (TLPO) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06175221 ↗ |
| Known as | TLPO | “The goal of this clinical trial is to learn about TLPO cancer vaccine in cases of solid tumor malignancies.” NCT06175221 ↗ |
| Modality | Vaccine | “autologous TLPO vaccine” NCT06175221 ↗ |